BioMarin Pharmaceutical (BMRN) : Zacks Investment Research ranks BioMarin Pharmaceutical (BMRN) as 3, which is a Hold recommendation. 12 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 16 research analysts is 1.38, which indicates as a Strong Buy.
BioMarin Pharmaceutical (BMRN) : 15 investment research analysts covering BioMarin Pharmaceutical (BMRN) have an average price target of $111.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $150 and the lowest target is $99 for the short term. Analysts expect the variance to be within $12.48 of the average price.
BioMarin Pharmaceutical (NASDAQ:BMRN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.34 and $77.98 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $81.13. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.81, notching a gain of 1.19% for the day. The total traded volume was 1,402,516 . The stock had closed at $79.86 on the previous day.
Also, BMO Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) The current rating of the shares is Outperform. The rating by the firm was issued on April 7, 2016. The company shares have dropped -41.96% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $151.75 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $83.89 and the 200 Day Moving Average price is recorded at $84.50.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).